|Articles|November 17, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Implications of the First Liquid IV Infliximab Biosimilar
2
GSK Bets $50M on LTZ’s Immune-Engager Platform for Next-Gen Cancer Treatment
3
Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program
4
Why 503B Compounding Pharmacies Choose Prefabricated POD® Cleanrooms
5
